Endocrine Abstracts

Introduction: Acromegaly is a rare and misdiagnosed disease characterized by somatotropic hypersecretion. The purpose of this study is to describe the epidemiological, clinical, para-clinical, therapeutic features of Acromegaly disease.

Patients and methods: This is a retrospective study including 10 patients with acromegaly in the Endocrinology Diabetology Department of Oujda’s Mohammed VI University Hospital, Morocco.

Results: The mean age at diagnosis was 49 years with a female predominance. The median diagnosis delay was 8 years. Acrofacial dysmorphic syndrome was the most frequent mode of revelation. Pituitary adenoma was the etiology in all cases, macroadenoma in nine patients and microadenoma in one patient. All our patients had complications at the moment of diagnosis: ante-pituitary insufficiency in 100% of cases, ophthalmological disorders in 70%, cardiorespiratory complications in 60%, diabetes mellitus was found in 50% and dyslipidemia in 30% of cases. All our patients had goiter. colic polyps was observed in 40%, bone deformities in 60% and arthralgia in 50%. 70% of patients underwent transsphenoidal pituitary surgery, and 80% have been treated by somatostatin analogs (Lanreotide LP 120 mg), given before surgery in four cases with non-invasive adenoma and in three cases as a second line therapy after incomplete tumor resection associated to radiotherapy (30%). Treatment with SA has normalized IGF1 levels in 62.5% of cases.

Conclusion: Early diagnosis of acromegaly is necessary to avoid complications. Its management should be discussed among multidisciplinary meetings.